Research protocols typically use daily dosing for 714 days during the induction phase, with therapeutic effects lasting 30+ days post-treatment despite complete plasma clearance within 12 hours of the final dose
Acute lung injury models show reduced inflammatory cell infiltration, increased superoxide dismutase activity, and decreased pro-inflammatory cytokine production
M., Sonoda-Crtes, R., Araujo, I
Biochem J 340:309
There is limited clinical evidence available
"This is crucial, given the strong link between MASH and cardiovascular, metabolic, and renal conditions, where semaglutide has already shown established health benefits." Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, essentially acting like the natural GLP-1 hormone to help regulate key metabolic processes including reducing appetite and lowering blood sugar